Phase III Comparison of Adjuvant Chemotherapy W/High-Dose Cyclophosphamide Plus Doxorubicin (AC) vs Sequential Doxorubicin Fol by Cyclophosphamide (A-C) in High Risk Breast Cancer Patients With 0-3 Positive Nodes (Intergroup, CALGB 9394)
Completed · Phase 3
Conditions studied: High Risk, Breast Cancer, Positive Nodes, Cyclophosphamide, Doxorubicin
In brief
To compare disease-free survival (DFS), overall survival (s), and toxicity of high-isk primary breast cancer patients with negative axillary lymph nodes or with one to three positive nodes treated with adjuvant high-dose chemotherapy with doxorubicin plus cyclophosphamide (AC), versus high-dose sequential chemotherapy with doxorubicin followed by cyclophosphamide (A--\>C).
Key facts
- Study ID
- NCT00590785
- Run by
- National Cancer Institute (NCI)
- People needed
- 60
- Starts
- 1996-08-13
- Expected to finish
- 2015-01-13
- Last updated by the study team
- 2017-08-25
Who can join
Age: any. Sex: female. Healthy volunteers: not accepted.
Where it is running
- Memorial Sloan Kettering Cancer Center — New York, New York, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.